Association of serum XXXX with cardiovascular prognosis in @entity453 .

@entity1 @entity1187 @entity295 @entity583 @entity731 @entity1904 @entity453 @entity65 @entity1851
BACKGROUND: @entity1904 (PCT) is an established biomarker for the diagnosis of @entity295 . Evidence is growing that PCT concentration correlates with the extent of @entity731 and prognosis in @entity1 with @entity453 ( @entity453 ). METHODS AND RESULTS: A total of 2,131 @entity1 with @entity453 were followed up for a median of 3.6 years. During follow-up, death from cardiovascular causes was registered in 95 @entity1 and non-fatal @entity583 in 85 @entity1 . Median and quartile 1 and 3 are reported for PCT concentration. @entity1 who died of cardiovascular causes had higher PCT concentrations [0.021 (0.012/0.036) ng/ml vs. 0.015 (0.010/0.023) ng/ml; P<0.0001]. @entity1 with @entity1187 had increased concentrations of PCT in relation to @entity1 with stable angina [0.016 (0.011/0.027) ng/ml vs. 0.014 (0.009/0.014) ng/ml; P for trend <0.0001]. PCT concentration across quartiles was associated with the event rate (P=0.026; log-rank test) and mortality (P=0.00018). On Cox regression analysis, elevated PCT concentration was related to cardiovascular mortality [hazard ratio (HR), 1.34; 95% confidence interval (CI): 1.08-1.65, P=0.0070], but not to @entity65 (HR, 1.09; 95%CI: 0.93-1.28, P=0.28). After adjustment for @entity1851 ( @entity1851 ), PCT did not provide additional prognostic information. CONCLUSIONS: PCT is associated with future cardiovascular mortality in @entity1 with @entity453 , but PCT is not superior to @entity1851 for prediction of outcome.
